These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8124969)

  • 1. Human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome.
    Tompkins RG
    Crit Care Med; 1994 Jan; 22(1):3. PubMed ID: 8124969
    [No Abstract]   [Full Text] [Related]  

  • 2. Interleukin-1 blockade attenuates mediator release and dysregulation of the hemostatic mechanism during human sepsis.
    Boermeester MA; van Leeuwen PA; Coyle SM; Wolbink GJ; Hack CE; Lowry SF
    Arch Surg; 1995 Jul; 130(7):739-48. PubMed ID: 7611862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome.
    Hawkins PN; Lachmann HJ; McDermott MF
    N Engl J Med; 2003 Jun; 348(25):2583-4. PubMed ID: 12815153
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of recombinant interleukin-1-receptor antagonist.
    Barriere SL; Pribble JP
    Am J Hosp Pharm; 1994 May; 51(9):1253, 1257. PubMed ID: 8042646
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist.
    Bresnihan B
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I96-8. PubMed ID: 10577983
    [No Abstract]   [Full Text] [Related]  

  • 6. Alternative views on the effects of recombinant interleukin-1-receptor antagonist.
    Vance-Bryan K; Hoey LL; Joslin SM
    Am J Hosp Pharm; 1994 Nov; 51(21):2724-7. PubMed ID: 7710539
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of chronic polyarthritis with a human recombinant interleukin 1 receptor antagonist].
    Rau R; Sander O; Musikic P
    Z Rheumatol; 1998 Oct; 57(5):312-9. PubMed ID: 9864837
    [No Abstract]   [Full Text] [Related]  

  • 8. Multiple sclerosis: longitudinal measurement of interleukin-1 receptor antagonist.
    Voltz R; Hartmann M; Spuler S; Scheller A; Mai N; Hohlfeld R; Yousry T
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):200-1. PubMed ID: 9048730
    [No Abstract]   [Full Text] [Related]  

  • 9. Beneficial response to interleukin 1 receptor antagonist in traps.
    Simon A; Bodar EJ; van der Hilst JC; van der Meer JW; Fiselier TJ; Cuppen MP; Drenth JP
    Am J Med; 2004 Aug; 117(3):208-10. PubMed ID: 15300976
    [No Abstract]   [Full Text] [Related]  

  • 10. The many worlds of reducing interleukin-1.
    Dinarello CA
    Arthritis Rheum; 2005 Jul; 52(7):1960-7. PubMed ID: 15986340
    [No Abstract]   [Full Text] [Related]  

  • 11. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.
    Fisher CJ; Dhainaut JF; Opal SM; Pribble JP; Balk RA; Slotman GJ; Iberti TJ; Rackow EC; Shapiro MJ; Greenman RL
    JAMA; 1994 Jun; 271(23):1836-43. PubMed ID: 8196140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From the Food and Drug Administration.
    Schwetz BA
    JAMA; 2002 Jan; 287(1):33. PubMed ID: 11754690
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful treatment of acute visual loss in Muckle-Wells syndrome with interleukin 1 receptor antagonist.
    Alexander T; Klotz O; Feist E; Rüther K; Burmester GR; Pleyer U
    Ann Rheum Dis; 2005 Aug; 64(8):1245-6. PubMed ID: 16014694
    [No Abstract]   [Full Text] [Related]  

  • 14. Kineret. Easing the pain of rheumatoid arthritis.
    Nursing; 2002 Apr; 32(4):26. PubMed ID: 11969009
    [No Abstract]   [Full Text] [Related]  

  • 15. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial.
    Fisher CJ; Slotman GJ; Opal SM; Pribble JP; Bone RC; Emmanuel G; Ng D; Bloedow DC; Catalano MA;
    Crit Care Med; 1994 Jan; 22(1):12-21. PubMed ID: 8124953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refractory relapsing polychondritis: rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra).
    Vounotrypidis P; Sakellariou GT; Zisopoulos D; Berberidis C
    Rheumatology (Oxford); 2006 Apr; 45(4):491-2. PubMed ID: 16510529
    [No Abstract]   [Full Text] [Related]  

  • 17. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.
    Opal SM; Fisher CJ; Dhainaut JF; Vincent JL; Brase R; Lowry SF; Sadoff JC; Slotman GJ; Levy H; Balk RA; Shelly MP; Pribble JP; LaBrecque JF; Lookabaugh J; Donovan H; Dubin H; Baughman R; Norman J; DeMaria E; Matzel K; Abraham E; Seneff M
    Crit Care Med; 1997 Jul; 25(7):1115-24. PubMed ID: 9233735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The trials of anakinra.
    Burls A; Jobanputra P
    Lancet; 2004 Sep 4-10; 364(9437):827-8. PubMed ID: 15351176
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment.
    Zeni F; Freeman B; Natanson C
    Crit Care Med; 1997 Jul; 25(7):1095-100. PubMed ID: 9233726
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al.
    Martinez-Taboada VM; Fontalba A; Blanco R; Fernández-Luna JL
    Arthritis Rheum; 2005 Jul; 52(7):2226-7. PubMed ID: 15986356
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.